Sun Pharmaceuticals acquired Ranbaxy in a $4 billion all-share deal in 2014. This created the fifth largest specialty generics company in the world. The merger strengthened Sun Pharma's global footprint, distribution network, and portfolio in key therapeutic areas. It gained access to Ranbaxy's brands and markets in regions like the US, Europe, Brazil, Russia, and China. However, Ranbaxy had been struggling financially prior to the acquisition due to regulatory and legal issues.

1. BY-
MOHIT VERMA
SUN PHARMA-RANBAXY

2.  The origin is from Latin acquīsītiōn-
, from acquīrere to acquire
 In case of a company, basically this act of
acquiring includes several dimensions-
1. Taking custody of records.
2. Taking possession of an asset by purchase.
3. Taking control of a firm by purchasing
51 percent (or more) of its voting shares.

5.  Sun Pharmaceuticals was established by Mr. Dilip
Shanghvi in 1983 in Vapi with five products to
analyse sickness.
 It is an Indian multinational pharmaceutical
company headquartered in Mumbai,
Maharashtra. It manufactures and sells
pharmaceutical formulations primarily in India
and the United States.

Today it has total asset of US$23 billion

It is the largest chronic prescription company in
India and a market leader in psychiatry, neurology,
cardiology.

7.  Ranbaxy is an Indian
multinational pharmaceutical company that was
incorporated in India in 1961. In 1973 and
Japanese pharmaceutical company Daiichi
Sankyo acquired a controlling share in 2008.
 By end of Dec 2010, the company's global sales
were US$1,178 million, with overseas markets
accounting for 75% of global sales
 (USA: 28%, Europe: 17%, Brazil, Russia, and
China: 29%). For the twelve months ending on 31
December 2006, the company's global sales were
US$1,300 million.

8.  The company met its sales targets for the latest
financial year, it has been incurring a net loss
and suffering a decline in net worth since 2011,
which can be attributed to a few key
circumstances..
 These include the settlement amount of US$ 515
million paid to the US Department of Justice in
May 2013 after civil and criminal charges were
brought against it for misrepresentation of
data and irregularities found in two of its
facilities in India.

9.  Diminution in the value of its investments
and a loss on foreign currency
option derivatives. Thus, the merger of the
company with Sun Pharma comes at a crucial
time when Ranbaxy is struggling to improve
its financial position.

10.  On 7 April 2014 Sun Pharmaceutical and Daiichi
Sankyo jointly announced the sale of the entire 63.4%
share from Daiichi Sankyo to Sun Pharma.
 $4 billion all-share deal. Under these agreements,
shareholders of Ranbaxy, were to receive a 0.8 share
of Sun Pharmaceutical for each share of Ranbaxy.
 After this acquisition, the partner Daiichi-Sankyo was
to hold a stake of 9% in Sun Pharmaceutical. The
combination of Sun Pharma and Ranbaxy created the
fifth-largest specialty generics company in the world
and the largest pharmaceutical company in India.

11.  The new entity will be the world’s fifth
largest specialty-generic Pharma company with sales
of US$ 4.2 billion.
 In the U.S., the merged entity will be No.1 in the
generic dermatology market and No. 3 in the branded
dermatology market.
 The merger will also improve Sun Pharma’s global
footprint in emerging Pharma markets like Russia,
Romania, Brazil, Malaysia and South Africa, offering
opportunities for better brand-building.
 It enable Sun Pharma to enhance its edge in acute
care, hospitals and OTC businesses with 31 brands
among India’s top 300 brands and a better
distribution network.